MicroRNA-155 is a critical regulator of regulatory T cells in OM-85 Broncho-Vaxom treated experimental models of allergic rhinitis

Xi Luo; Hehong Li; Rongshan Chen; Yinhui Zeng; Wenlong Liu; Qingxiang Zeng; Xi Luo; Hehong Li; Rongshan Chen; Yinhui Zeng; Wenlong Liu; Qingxiang Zeng

doi:10.3934/Allergy.2024002

AIMS Allergy and Immunology

2024, Volume 8, Issue 1: 8-17. doi: 10.3934/Allergy.2024002

Previous Article Next Article

Research article

MicroRNA-155 is a critical regulator of regulatory T cells in OM-85 Broncho-Vaxom treated experimental models of allergic rhinitis

1.
Department of Otolaryngology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, China
2.
Department of Medical Imaging, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, China
3.
Department of Respiratory Medicine, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Child Health, Guangzhou, 510623, China
† These three authors contributed equally.

Received: 05 November 2023 Revised: 31 December 2024 Accepted: 12 January 2024 Published: 24 January 2024

Background
Bacterial lysates could alleviate the clinical symptoms of allergic rhinitis (AR) and decrease the recurrent rate of AR through regulation of regulatory T cell (Treg) cells. However, the molecular regulatory mechanisms of bacterial lysates to Treg are still unclear.

Objective
We aimed to investigate the importance of microRNA-155 (miR-155) to Treg cells function in OM-85 Broncho-Vaxom (OM-85 BV) treated experimental mouse models of AR.

Methods
AR mouse models were established and treated by intranasal administration of OM-85 BV to investigate the role of bacteria lysate for Treg cell function. The proliferation of Treg cells in peripheral blood was examined. The mRNA levels of IL-10, transforming growth factor-β (TGF-β) were examined by real-time PCR. miR-155 mimics and inhibitor were used to verify the role of miR-155 for Treg cells function.

Results
OM-85 BV, miR-155 mimics or their combination reduced total cells, lymphocytes, neutrophils and eosinophils in nasal lavage fluid of AR mouse models and improved allergic symptoms. OM-85 BV promoted the proliferation of Treg and the expression of Foxp3, IL-10 and TGF-β both in vivo and in vitro. The miR-155 enhanced the proliferation and function of Treg.

Conclusions
MiR-155 promotes Treg cells function in OM-85 BV bacteria lysate treated experimental models of AR and alleviate the upper airway allergic inflammation in AR mice.
- allergic rhinitis,
- bacteria lysate,
- OM-85 Broncho-Vaxom,
- regulatory T cell,
- miR-155
Citation: Xi Luo, Hehong Li, Rongshan Chen, Yinhui Zeng, Wenlong Liu, Qingxiang Zeng. MicroRNA-155 is a critical regulator of regulatory T cells in OM-85 Broncho-Vaxom treated experimental models of allergic rhinitis[J]. AIMS Allergy and Immunology, 2024, 8(1): 8-17. doi: 10.3934/Allergy.2024002

Related Papers:

Abstract

Background

Bacterial lysates could alleviate the clinical symptoms of allergic rhinitis (AR) and decrease the recurrent rate of AR through regulation of regulatory T cell (Treg) cells. However, the molecular regulatory mechanisms of bacterial lysates to Treg are still unclear.

Objective

We aimed to investigate the importance of microRNA-155 (miR-155) to Treg cells function in OM-85 Broncho-Vaxom (OM-85 BV) treated experimental mouse models of AR.

Methods

AR mouse models were established and treated by intranasal administration of OM-85 BV to investigate the role of bacteria lysate for Treg cell function. The proliferation of Treg cells in peripheral blood was examined. The mRNA levels of IL-10, transforming growth factor-β (TGF-β) were examined by real-time PCR. miR-155 mimics and inhibitor were used to verify the role of miR-155 for Treg cells function.

Results

OM-85 BV, miR-155 mimics or their combination reduced total cells, lymphocytes, neutrophils and eosinophils in nasal lavage fluid of AR mouse models and improved allergic symptoms. OM-85 BV promoted the proliferation of Treg and the expression of Foxp3, IL-10 and TGF-β both in vivo and in vitro. The miR-155 enhanced the proliferation and function of Treg.

Conclusions

MiR-155 promotes Treg cells function in OM-85 BV bacteria lysate treated experimental models of AR and alleviate the upper airway allergic inflammation in AR mice.

Acknowledgments

This study was supported by grants from the Science and Technology Program of Guangzhou (No.202201011844, No. 202201020600), Scientific Research Capacity Improvement Project of Guangzhou Medical University (02-410-2302151XM).

Conflict of interest

All authors declare no conflicts of interest in this paper.

References

[1]	Genuneit J, Standl M (2022) Epidemiology of allergy: Natural course and risk factors of allergic diseases. Handb Exp Pharmacol 268: 21-27. https://doi.org/10.1007/164_2021_507
[2]	Li F, Zhou Y, Li S, et al. (2011) Prevalence and risk factors of childhood allergic diseases in eight metropolitan cities in China: a multicenter study. BMC Public Health 11: 437. https://doi.org/10.1186/1471-2458-11-437
[3]	Barnes PJ (2011) Pathophysiology of allergic inflammation. Immunol Rev 242: 31-50. https://doi.org/10.1111/j.1600-065X.2011.01020.x
[4]	Zhang Y, Lan F, Zhang L (2021) Advances and highlights in allergic rhinitis. Allergy 76: 3383-3389. https://doi.org/10.1111/all.15044
[5]	Tomazic PV, Lang-Loidolt D (2021) Current and emerging pharmacotherapy for pediatric allergic rhinitis. Expert Opin Pharmacother 22: 849-855. https://doi.org/10.1080/14656566.2020.1808622
[6]	Janeczek K, Kaczyńska A, Emeryk A, et al. (2022) Perspectives for the use of bacterial lysates for the treatment of allergic rhinitis: A systematic review. J Asthma Allergy 15: 839-850. https://doi.org/10.2147/jaa.S360828
[7]	Kaczynska A, Klosinska M, Janeczek K, et al. (2022) Promising immunomodulatory effects of bacterial lysates in allergic diseases. Front Immunol 13: 907149. https://doi.org/10.3389/fimmu.2022.907149
[8]	Koatz AM, Coe NA, Cicerán A, et al. (2016) Clinical and immunological benefits of OM-85 bacterial lysate in patients with allergic rhinitis, asthma, and COPD and recurrent respiratory infections. Lung 194: 687-697. https://doi.org/10.1007/s00408-016-9880-5
[9]	Specjalski K, Jassem E (2019) MicroRNAs: Potential biomarkers and targets of therapy in allergic diseases?. Arch Immunol Ther Exp 67: 213-223. https://doi.org/10.1007/s00005-019-00547-4
[10]	Zhu YQ, Liao B, Liu YH, et al. (2019) MicroRNA-155 plays critical effects on Th2 factors expression and allergic inflammatory response in type-2 innate lymphoid cells in allergic rhinitis. Eur Rev Med Pharmacol Sci 23: 4097-4109. https://doi.org/10.26355/eurrev_201905_17911
[11]	Johansson K, Malmhäll C, Ramos-Ramírez P, et al. (2017) MicroRNA-155 is a critical regulator of type 2 innate lymphoid cells and IL-33 signaling in experimental models of allergic airway inflammation. J Allergy Clin Immunol 139: 1007-1016. https://doi.org/10.1016/j.jaci.2016.06.035
[12]	Zeng Q, Liu W, Luo R, et al. (2019) MicroRNA-181a and microRNA-155 are involved in the regulation of the differentiation and function of regulatory T cells in allergic rhinitis children. Pediatr Allergy Immunol 30: 434-442. https://doi.org/10.1111/pai.13038
[13]	Lee SH, Kim HJ, Lee SY, et al. (2023) Broncho-Vaxom bacterial lysate prevents asthma via acetate enhancement in mouse model. Pediatr Allergy Immunol 34: e14018. https://doi.org/10.1111/pai.14018
[14]	Fu R, Li J, Zhong H, et al. (2014) Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3β-related T regulatory cell insufficiency. PLoS One 9: e92912. https://doi.org/10.1371/journal.pone.0092912
[15]	Shen Y, Li L, Chen W, et al. (2023) Apolipoprotein E negatively regulates allergic airway inflammation and remodeling in mice with OVA-induced chronic asthma. Int Immunopharmacol 116: 109776. https://doi.org/10.1016/j.intimp.2023.109776
[16]	Lau S, Gerhold K, Zimmermann K, et al. (2012) Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol 129: 1040-1047. https://doi.org/10.1016/j.jaci.2012.02.005
[17]	Janeczek KP, Emeryk A, Rapiejko P (2019) Effect of polyvalent bacterial lysate on the clinical course of pollen allergic rhinitis in children. Postepy Dermatol Alergol 36: 504-505. https://doi.org/10.5114/ada.2019.87457
[18]	Meng Q, Li P, Li Y, et al. (2019) Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa. Rhinology 57: 451-459. https://doi.org/10.4193/Rhin19.161
[19]	Han L, Zheng CP, Sun YQ, et al. (2014) A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. Am J Rhinol Allergy 28: 110-116. https://doi.org/10.2500/ajra.2013.27.4021
[20]	Kohlhaas S, Garden OA, Scudamore C, et al. (2009) Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 182: 2578-2582. https://doi.org/10.4049/jimmunol.0803162
[21]	Schjenken JE, Moldenhauer LM, Zhang B, et al. (2020) MicroRNA miR-155 is required for expansion of regulatory T cells to mediate robust pregnancy tolerance in mice. Mucosal Immunol 13: 609-625. https://doi.org/10.1038/s41385-020-0255-0

Reader Comments

Your name:*

Email:*
© 2024 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)